Activation of the glucagon-like peptide 1 (GLP-1 ... Semaglutide is a GLP-1 receptor agonist that has been approved by the US Food and Drug Administration and is currently marketed in various dosage ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 2 ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Even after dropping 1,300 bills to focus on the budget, the Florida Legislature passed more than 100 new laws that start July ...

More than 70 new laws take effect in Florida on July 1, 2025.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...